We used the following primary antibodies: mouse monoclonal anti-PV (1:2000, Sigma-Aldrich), CB (1:2000, Sigma-Aldrich), calretinin (CR; 1:10000, Millipore, Billerica, MA, USA), and glutamate decarboxylase 67 (GAD67) (1:10,000, Millipore); rat monoclonal anti-BrdU (1:100; Abcam, Cambridge, MA, USA); rabbit polyclonal anti-gamma-aminobutyric acid (GABA; 1:1000, Sigma-Aldrich) and anti-Ki67 (1: 10, Ylem, Rome, Italy), and neuropeptide Y (NPY, 1: 2000, Sigma-Aldrich); and goat polyclonal anti-DCX (1:200, Santa Cruz Biotechnology, Dallas, TX, USA). We also used the following secondary antibodies: Alexa Fluor 488 and 594 goat anti-mouse IgG (both 1:200, Life Technologies, Carlsbad, CA, USA), Cy3 goat anti-mouse IgM (1:200, Millipore), and Alexa Fluor 594 goat anti-rabbit IgG and anti-rat IgG (both 1:200, Life Technologies). Biotinylated Wisteria floribunda agglutinin (1:200, Sigma-Aldrich), followed by Alexa Fluor 488 conjugated to streptavidin (10 μg/ml), was used to label PNNs using the method described above [12 (link)].
Free full text: Click here